Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury - (NOSTRA Phase III Trial): A Confirmatory, Placebo-controlled, Randomised, Double Blind, Multi-centre Study

Trial Profile

Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury - (NOSTRA Phase III Trial): A Confirmatory, Placebo-controlled, Randomised, Double Blind, Multi-centre Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Ronopterin (Primary)
  • Indications Brain injuries
  • Focus Registrational; Therapeutic Use
  • Acronyms NOSTRA-III
  • Sponsors vasopharm BIOTECH
  • Most Recent Events

    • 06 Sep 2016 According to a Vasopharm media release, data read-out (final clinical report) of the study is estimated for mid-2019.
    • 06 Sep 2016 According to a vasopharm media release, first patient has been enrolled in this trial.
    • 06 Sep 2016 Planned number of patients changed from 220 to 232, according to a Vasopharm media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top